drugset / Trial / NCT01999270

Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors

NCT01999270

Phase 1 Completed 6 enrolled Washington University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

To determine if FDOPA-PET/MRI imaging can predict response to treatment of bevacizumab.

Timeline

Start
2013-04
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody Intravenous
Background Irinotecan Small molecule Intravenous